Basic and Clinical Pharmacology of the Acetylcholine Receptor: Implications for the Use of Neuromuscular Relaxants

JA Jeevendra Martyn

Department of Anaesthesia, Massachusetts General Hospital and Shriners Burns Institute, and Harvard Medical School, Boston, MA, USA

(Received for publication on November 14, 1994)

Abstract. Multiple factors alter the interaction of muscle relaxants with the neuromuscular (NM) junction. This review focused on the aberrant responses caused, principally, by alterations in acetylcholine receptor (AChR)s. It should be emphasized that prejunctional and post AChR factors also may alter sensitivity to muscle relaxants and also cause functional changes, including muscle weakness. The pharmacokinetic and pharmacogenetic factors which cause aberrant responses have not been discussed. Many pathological states increase or decrease AChRs and this has been enumerated in Table 1. Increased AChRs is associated with resistance to the NM effects of nondepolarizing (ND)MR. With proliferation of AChR, the exaggerated release of potassium with depolarization from succinylcholine (SCh) can be attributed to increased AChR number; qualitative changes in AChR number may also play a role. Preliminary studies using potassium channel inhibitors indicate that potassium channels do not play a major role in the hyperkalimic response to SCh. During acute organophosphorus poisoning, SCh should be avoided because its metabolic breakdown would be impaired; the requirement for NDMR may be increased because of increased competition with high levels of ACh at the neuromuscular junction. With the chronic presence of ACh at the neuromuscular junction there would be down regulation and the responses would be similar to that seen in myasthenia gravis. All of these responses to SCh and NDMR which are associated with concomitant changes in AChR are analogous to drug-receptor interactions observed in other biological systems. (Keio J Med 44 (1): 1–8, March 1995)

Key words: acetylcholine receptor, neuromuscular agents, succinylcholine, d-tubocurarine, pharmacology

Neuromuscular (NM) relaxants are used in the emergency room, operating room and in the Intensive Care Unit to effect muscle relaxation for intubation, for surgery as well as for effective mechanical ventilation with positive end expiratory pressure. Shortly after the introduction of NM relaxants to clinical practice in 1942, it became apparent that certain pathological states and/or genetic factors could be associated with both hyper- and hypo-sensitivity to both agonist-type or depolarizing, and antagonist or nondepolarizing (ND)MR. (Depolarizing relaxants such as succinylcholine, SCh and decamethonium should be considered acetylcholine receptor (AChR) agonists since their pharmacological actions are like acetylcholine (ACh) in that, at least initially, they stimulate AChRs. NDMRs such as tubocurarine (dTC) and vecuronium are competitive antagonists of the AChRs because they competitively inhibit the effects of ACh). Cardiac arrest, following succinylcholine was reported to occur in certain patients. The availability of quantitative assays for drug concentrations and receptors, together with electrophysiologic and immunologic techniques, have enabled investigators to correlate alterations in sensitivity of NM relaxants to pharmacokinetic, pharmacodynamic or to pharmacogenetic causes. Pharmacokinetics refers to changes in distribution, clearance and/or elimination of a drug. Pharmacodynamics examines the relationship of a drug concentration (in blood or tissue) to pharmacologic effects and, therefore, documents the sensitivity of the target organ to a drug. Pharmacogenetics is the study of the role of genetics (and environment) in variations to drug response. Examples of genetically mediated abnormal response to muscle relaxants include prolonged recovery, contracture or malignant hyperthermic response to succinylcholine. This review will specifically focus on the qualitative and quantitative changes in the nicotinic acetylcholine recep-
tors (AChRs) at the muscle membrane and its relationship to NM relaxant sensitivity. Pathological states, including iatrogenic factors and the molecular mechanisms, which may play a role in these AChR changes, will be also discussed. Pharmacokinetic and pharmacogenetic causes of aberrant responses to NM relaxants is not within the scope of this paper.

Basic Biology and Pharmacology of the AChRs

The classical pharmacological dogma regarding up-regulation (increased numbers) and down-regulation (decreased numbers) of receptors, and its relationship to agonists and antagonists responses can be invoked to explain the AChR-mediated abnormal responses to muscle relaxants.3,4 It must be emphasized, however, that in addition to AChR changes, prejunctional (nerve-related) and postjunctional (muscle-related) changes can also affect NM transmission and sensitivity to muscle relaxants. The receptor theory proposes that up-regulation of receptors is associated with increased sensitivity to agonists and decreased sensitivity to antagonists.4 This upregulation and increased sensitivity to agonists may result in lethal hyperkalemia when SCh-induced depolarization causes massive potassium efflux through the up-regulated AChRs. Down-regulation is associated with decreased sensitivity to agonists (SCh) and increased sensitivity to antagonists (e.g. dTC). Clinical conditions in which there is an increase or decrease in AChR numbers are indicated in Table 1.

These aberrant agonist and antagonists responses related to up- and down-regulation of AChRs is complicated by the potential presence or absence of another isoform of AChR at the muscle membrane.5 The AChRs present in the normal, adult, innervated muscle are considered mature receptors. A mature or junctional receptor is formed of five subunit proteins termed α, β, ε, and σ in the ratio of 2:1:1:1. When there is deprivation of neural influence, as in denervation, a new form of receptor with a subunit composition of α, β, γ and σ in Table 1 Pathological States Associated with Changes in Acetylcholine Receptors

<table>
<thead>
<tr>
<th>Increased AChRs with Resistance to NDMR and Hyperkalemia to Agonists</th>
<th>Decreased AChRs with Sensitivity to NDMR and Resistance to Agonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any neurologic deficit</td>
<td>Myasthenia gravis</td>
</tr>
<tr>
<td>Direct muscle trauma</td>
<td>Organophosphorus poisoning</td>
</tr>
<tr>
<td>Thermal trauma</td>
<td>Chronic anticholinesterase treatment</td>
</tr>
<tr>
<td>Disease atrophy</td>
<td>Critical illness</td>
</tr>
<tr>
<td>Prolonged use of NDMR</td>
<td>Prolonged NDMR use</td>
</tr>
<tr>
<td>Severe infection</td>
<td>Severe infection</td>
</tr>
</tbody>
</table>

Fig 1 AChR channels with subunits (α, β, ε and σ or α, β, γ and σ) around the central cation channel. The mature receptor is seen in innervated muscle while the immature receptor is seen in denervated or fetal tissue. The binding of ACh results in opening of the channel. The mean open channel times differ between the two types of AChR.
and partial intrinsic agonist activity present in some of the competitive antagonists (e.g. dTC).

**Clinical Syndromes Associated with Upregulation of AChRs**

**Denervations syndromes**

The relationship of upper or lower motor neuron injury to succinylcholine-induced hyperkalemia has received attention in many reports. More recent studies have documented that upper motor neuron injury (e.g., stroke, transection of the spinal cord) results in resistance to the effects of NDMR in the affected limb. The appearance of denervation-like changes in the presence of an anatomically intact motor nerve supports the concept that even following central denervation, there is transsynaptic degeneration of the α-motor neurons probably related to deprivation of trophic factors or inputs that are normally received from descending motor pathways. Of note, is the finding that decreased sensitivity to competitive antagonists could be observed not only on the affected (stroked) side but also on the unaffected (normal) side.

Complete transection of a motor nerve results in Wallerian degeneration. Although the response to succinylcholine could be studied in a muscle that has been damaged in this fashion, the sensitivity to NDMR can not be studied because nerve-mediated twitch tension cannot be elicited. The hypothesis that lower motor neuron injury, with associated proliferation of AChRs, induces resistance to NDMR was tested following partial denervation. The left gastrocnemius was denervated by a 75–80% lesion of the sciatic nerve. The effective dose for 95% twitch depression was studied in the denervated gastrocnemius and compared to the contralateral undenervated and sham-injured (control: gastrocnemius muscles approximately 2 weeks after injury). The dose and plasma concentrations of dTC for twitch inhibition of the denervated leg was significantly higher than contralateral or sham-operated muscles. There was a significant correlation ($R^2 = 0.73$) between dose and AChR number. One can therefore conclude that following partial denervation (and possibly during reinnervation) of a lower motor neuron injury there is resistance to NDMR on that side but the contralateral neuromuscular responses are unaffected.

**Burns**

Burned and denervated patients share a hypersensitivity response to Ach or ScH and hyposensitivity response to NDMR. The hypothesis that an upregulation of AChRs occurs at the muscle membrane at sites distant from the burn has been tested in the rat after an approxi-

![Fig 2](image-url) Levels of AChR (fmol.mg$^{-1}$protein) at 10, 14, 21 and 28 days after burn. Column shows mean ±SEM. Significant increases in AChRs were seen at varying times after burn.
due to upregulated AChRs. Both dose- and concentration-response curves to NDMR are also shifted to the right following immobilization. Although previous studies of single limb immobilization have documented no lethal hyperkalemic response to SCh, recent studies with bilateral immobilization for 4 weeks have indicated that profound hyperkalemic response to SCh (see below).14

**Infection**

Inflammation or infection alters the neuromuscular junction and response to SCh and NDMR. Bacterial toxins such as those released by clostridium (botulinium or tetanus) inhibit the release of ACh which if prolonged can increase AChRs and cause a denervation-like syndrome. Injection of toxin from E. Coli (endotoxicosis) also has been shown to cause 3 to 5-fold rightward shift in the dose-response curves to dTC (Table 2).15 Weight loss and atrophy, secondary to the effects of toxin, do not appear to be factors, because similar atrophy and weight loss during malnutrition did not reproduce these alterations in response to NDMR. Reinforcement of these observations, relative to infection and muscle relaxants are reports of exaggerated potassium response to SCh in patients with serious infections of one or more weeks.16

**Increase of AChRs by NDMRs**

Classical receptor pharmacology suggests that chronic antagonism or inhibition of a receptor will result in upregulation of these receptors. Although this hypothesis has been tested relative to AChRs, these studies; however, were confounded by the fact that the competitive antagonist simultaneously caused complete or incomplete paralysis of muscles (immobilization).17 These investigators, in fact, concluded that immobilization was the cause of the spread of AChRs. The resting membrane potential and input resistance of the muscle fibers that had been paralyzed were similar to those in denervated muscle.17

**dTc upregulates AChRs in mobile animals:** The hypothesis that continuous subluminal (subparalytic) competitive antagonism of AChRs (i.e. antagonism in the absence of immobilization) induces a proliferation of AChRs has been recently tested using dTC as the test drug.19 NDMRs could be administered without paralysis because of the high margin of safety of NM transmission. The attendant pharmacodynamic (NM) responses to dTC were also studied. Chronic subparalytic antagonism of AChRs was achieved in rats by infusion of dTC for 2 weeks through

---

**Table 2** Neuromuscular Dynamics During Endotoxicosis or Malnutrition

<table>
<thead>
<tr>
<th>Condition</th>
<th>E_{max} (g)</th>
<th>ED_{50} (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>59 ± 1.5</td>
<td>0.08 ± 0.01</td>
</tr>
<tr>
<td>¼ LD_{50} Endotoxin (1 wk)</td>
<td>21 ± 2.6</td>
<td>0.32 ± 0.1*</td>
</tr>
<tr>
<td>¼ LD_{50} Endotoxin (2 wks)</td>
<td>23 ± 2.7</td>
<td>0.29 ± 0.07*</td>
</tr>
<tr>
<td>Protein Malnutrition (12 wks)</td>
<td>20 ± 0.3</td>
<td>0.08 ± 0.03</td>
</tr>
</tbody>
</table>

*p < 0.01; Mean ± SE: Emax = gastrocnemius tension.15*
osmotic mini pumps. No difference in weight gain or mobility was observed between saline or dTC-infused groups. The experimental group was able to develop a baseline tension similar to that of controls (no paralytic effect) despite the presence of plasma dTC concentrations (0.4 μg/ml) that would normally depress twitch to 60% if administered acutely. These pharmacodynamic alterations were associated with increased extrajunctional AChRs.

**dTC accentuates the burn-induced upregulation of AChRs:** In more recent studies we have examined whether the administration of a competitive antagonist of the AChR (e.g. dTC) accentuates the upregulation of AChRs induced by burn trauma (Table 4). The protocol was somewhat similar to that described above, except that dTC was infused directly into the left gastrocnemius. There were no apparent differences in movement eating behavior or weight after implantation of the pumps in burned animals receiving dTC or saline; the presence of withdrawal reflex to pinch confirmed the absence of paralysis even in the dTC-infused group.

The left gastrocnemius AChR numbers (with PE60 tubing placed in close proximity to it) were consistently higher than the contralateral AChRs within the same group. The AChRs on the right and left gastrocnemius in the burn group receiving saline were higher than sham-injured groups, but did not reach statistical significance. The burn group receiving dTC infusion to the left gastrocnemius, however, had significant elevations of AChRs.

**Table 3** Neuromuscular Pharmacodynamics and AChR Changes Following Chronic dTC Infusion

<table>
<thead>
<tr>
<th>Condition</th>
<th>dTC-Exposed</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junctional AChRs</td>
<td>15.4 ± 2.1</td>
<td>13.7 ± 2.0</td>
</tr>
<tr>
<td>(fmoles/mg protein)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extrajunctional AChRs</td>
<td>19.8 ± 1.8*</td>
<td>13.4 ± 1.8</td>
</tr>
<tr>
<td>(fmoles/mg protein)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dTC concentration for twitch</td>
<td>0.83 ± 0.04*</td>
<td>0.50 ± 0.15</td>
</tr>
<tr>
<td>inhibition (μg/ml)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* p < 0.05 vs controls; values are Mean ± SE.18

**Table 4** AChRs Following Burns with/without dTC Infusion (fmoles/mg protein)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sham Burns with Saline Infusion (n = 10)</th>
<th>Burns with Saline Infusion (n = 9)</th>
<th>Burns with dTC Infusion (n = 15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left gastrocnemius</td>
<td>7.13 ± 0.47®</td>
<td>9.84 ± 1.21™</td>
<td>13.93 ± 0.95**</td>
</tr>
<tr>
<td>right gastrocnemius</td>
<td>5.72 ± 0.47</td>
<td>7.18 ± 0.88</td>
<td>7.33 ± 0.43</td>
</tr>
</tbody>
</table>

®: p < 0.05 left gastrocnemius compared to right within each group. ™: p < 0.01 compared to ipsilateral muscle in sham-burned controls. #: p < 0.05 compared to burned-group receiving saline.19

**dTC accentuates immobilization-induced upregulation of AChRs:** The effects of immobilization alone, and dTC infusion alone and the combination of the two perturbations on AChR number were tested in separate experiments (in the absence of burn) in the rat. The role and importance of the immobilization and/or dTC-induced AChR changes on hyperkalemia associated with SCh administration was tested by measuring plasma K+ levels at baseline and at 5 minutes following SCh. Bilateral hind limb immobilization was achieved by plaster cast. Four groups of animals were tested (Table 5). Immobilization or dTC infusion alone significantly increased AChR number. The combination of the immobilization with dTC infusion caused the highest AChR proliferation. In all groups, the administration of SCh resulted in significant increases in plasma K+ levels. The plasma K+ response to SCh, however, was highest following the combination of immobilization and dTC infusion: that is, the hyperkalemia was directly related to AChR number.

The conclusions that can be made from these dTC-infusion studies are the following: subparalytic doses of dTC can upregulate AChR. Burn injury-induced increases in AChRs is exaggerated by concomitant administration of even subparalytic doses of dTC. Concomitant administration of subparalytic doses of dTC with immobilization causes profound increases in AChR. Higher the AChR number, more profound the hyperkalemia to SCh. Higher doses and/or longer infusions of dTC or nondepolarizing muscle relaxants may cause greater increases in AChR number. Administration of dTC or other nondepolarizing muscle relaxants to patients to facilitate mechanical ventilation (as in the ICU setting) may result in further exaggeration of the aberrant responses to neuromuscular relaxants including hyperkalemia to SCh.

**Potassium (K+) Channels in the Hyperkalemic Response to SCh**

SCh continues to be the drug of choice when there is indication for fast onset of muscle relaxation (e.g. rapid
intubation, laryngospasm). SCh also has the advantage of short duration of action. As indicated in the previous section many pathological states or iatrogenic factors induce an upregulation of AChRs throughout the muscle membrane. When SCh is administered in the presence of upregulated AChRs, depolarization of the whole muscle membrane occurs which causes massive efflux of K⁺ from the cell into plasma resulting in potentially lethal hyperkalemia. Both AChRs and K⁺ channels leak K⁺ from the cell during depolarization. The contribution of potassium channels to the hyperkalemia following SCh was tested in the following experiments in the denervation model. Potassium channel blockers, 4-aminopyridine (4-AP) and tetraethylammonium (TEA) were used to block the K⁺ channels on the muscle membrane following which SCh was administered.

After 2 weeks of bilateral sciatic nerve denervation to rats, the plasma K⁺ response to SCh (3 mg/kg) was studied. The rise in plasma K⁺ levels induced by SCh was significantly greater in denervated rats (2.9 ± 0.3 Meq/L, n = 6) than on sham-operated controls (0.7 ± 0.1, n = 6). Pretreatment with either 4-AP (3 or 5 mg/kg) or TEA (20 or 40 mg/kg) failed to significantly inhibit the rise in K⁺. At doses of 60 mg/kg of TEA attenuation of the hyperkalemia to SCh was observed (1.2 ± 0.3 meq/L, n = 6, p<0.05). However at this dose, twitch tension responses were also decreased to 20% of control response (80% muscle paralysis), suggesting that the inhibition of hyperkalemia was related more to inhibition of AChR ion channel and not the K⁺ channel. These studies, therefore, indicate that K⁺ channels may not play a significant role in the hyperkalemia to SCh. Thus K⁺ channel blockers may not be clinically useful for the prevention of hyperkalemia to SCh.

Molecular Mechanism of Upregulation of AChRs in Burns

Expression of γ-subunit mRNA levels

Burn injury and other critical illnesses are associated with functional and pharmacological changes in skeletal muscle. An important functional change is muscle weakness which results in decreased mobilization, hypoventilation and ventilatory failure. The aberrant pharmacological responses has already been alluded to. It is unclear if the upregulation of AChRs associated with burn injury and critical illness, although smaller in magnitude, simulates that seen with denervation in terms of expression of immature receptors. With denervation the genes for the immature AChRs are activated where the γ-subunit substitutes for the ε-subunit protein. A smaller single channel conductance and a 2 to 10 fold longer mean open channel time is associated with the immature receptor. Clinical conditions with long mean open channel time are associated with severe muscle weakness and atrophy of muscles. Slow channel or γ-type AChRs usually present only in the non-innervated muscle and in congenital slow channel syndromes may be present in burn injury to explain the muscle weakness. In the following molecular biology experiments we have attempted to characterize if increased expression of γ-subunit AChR occurs following burn injury.

We subjected RNA, isolated from gastocnemius muscle, to Northern Blot analysis with AChR specific cDNA probes. Densitometric analysis of the autoradiograms (normalized to GAPDH mRNA, internal control) indicated significant increases in only the α-subunit in muscle from animals with thermal injury but the ε, β and σ subunit mRNA levels were unchanged (Fig 4). Surprisingly, the expression of the γ-subunit of the AChR were not different between burned and control groups. It was, however, visualized in the RNA isolated from both embryonic and early postnatal muscle samples, confirming the ability of our cDNA probes to detect γ-subunit. An additional hallmark of denervation-response in skeletal muscle is a dramatic increase in the expression of transcripts that encode the myogenic regulatory proteins, including myoD and myogenin. RNAs from both control and thermally injured rats were, therefore characterized...
for their expression of myoD which was not altered in burns. These recent findings are consistent with our previous studies. The absence in changes in myoD and γ-subunit mRNA levels, thus confirm the absence of a denervation-like state or nerve-mediated cause to account for the proliferation of AChR following burn injury.

**Catecholamine-effects on AChRs**

Although catecholamines have been shown to increase breakdown of muscle protein, chronic administration of α2-adrenoceptor agonist, clenbuterol, has been shown to decrease protein catabolism and reduce body fat content not only in normal animals, but also in catabolic states such as diabetes, burn injury and muscle denervation. (Adrenergic receptors of the β2-type have been identified in the skeletal muscles of rats and humans.) Because of the association between weight loss (increase protein turnover) and increased AChRs in muscle, prevention of muscle wasting by clenbuterol may prevent some of the functional and pharmacological aberrations associated with burn injury. In the following experiments, using clenbuterol as a catecholamine-agonist and by administering it to normal and burned animals, we also tested the effects of catecholamine-stress on AChRs and expression of AChR subunit transcripts.

The administration of clenbuterol (for 14 days) resulted in a significant enhancement of weight gain in both burned and sham burned animals. AChRs in burned animals were significantly higher than in sham burned animals. The administration of clenbuterol to sham-burned animals also resulted in significant increases in AChRs compared to drug-free sham burned animals. Clenbuterol treatment to burned animals resulted in doubling of AChRs relative to other groups. Burn injury alone increased transcripts of α-subunit only. The administration of clenbuterol to sham-burn animals did not result in any transcriptional effects. The administration of clenbuterol to burned rats, however, caused a significant expression of α, β, α and ε subunit transcripts with no changes in γ-subunit or in myogenic regulatory proteins myoD and myogenin. These studies, therefore, indicate that clenbuterol has anabolic effects in burned and sham burned rats but does not attenuate AChR changes of burn trauma. The absence of increase in all subunit mRNA levels or of myogenic regulatory proteins confirms that the upregulation of AChR in burns is not related to a prejunctional, denervation-like phenomenon. Increased translational activity, stability of the receptor, or cAMP-mediated assembly of the receptors may account for the AChR changes in burns. The concomitant administration of clenbuterol (catecholamine-stress) in association with burn increased the mRNA levels of mature subunits only (no increase in γ-subunit increase) suggesting that this increase in AChRs may be a gene-mediated effect.

**Downregulation of AChRs**

Decrease of AChRs is a less common phenomenon although it is seen in certain pathological states including myasthenia gravis and chronic cholinesterase inhibition. Hyposensitivity to agonists (ACh and SCh), and increased

<table>
<thead>
<tr>
<th>Table 6: Size of Burn, Wet Weights, and AChR Number (Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Burn Size At Day 0 (%)</strong></td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Sham-Burn With No Clenbuterol (n = 11)</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>2.13 ± 0.06</td>
</tr>
<tr>
<td>5.57 ± 0.59</td>
</tr>
</tbody>
</table>

*Significant difference from sham burned group. **Significant difference from burned group.
sensitivity to NDMR will be observed (Table 1).

**Myasthenia gravis**

Myasthenia gravis is a disorder causing muscle weakness that becomes worse with repeated voluntary activity. Antibodies against AChRs are detectable in about 80% of patients. The majority of the antibodies are directed against the AChR and seem to bind to a distinct region on the surface of the AChR subunit, designated the main immunogenic region. The pathophysiology of myasthenia gravis should be contrasted with another auto-immune-mediated disease of the neuromuscular junction, namely Lambert-Eaton Myasthenic Syndrome (LEMS) which is a prejunctional phenomenon affecting voltage-gated calcium channel of the nerve terminal.

**Chronic cholinesterase inhibition**

The complementary hypothesis, that chronic agonism of AChR results in down regulation of receptor has also been tested. Voltage clamp electrophysiologic techniques and bungarotoxin binding studies have confirmed a reduction in the number of functional AChRs at the neuromuscular junction without affecting channel properties. Clinical situations in which pathologic elevations of ACh activity could occur, include an overdose of cholinesterase inhibitors in the treatment of myasthenia gravis, chronic administration of reversible cholinesterase inhibitors as prophylaxis during threat of chemical warfare, and acute and chronic exposure to organophosphorus insecticide compounds.

Acknowledgements: This study was partly supported by Grants from NIH RO-1 GM 3156911 and Shriners Burns Institute.

References

12. Pavlin E, Howard M, Slattery JT: Large burns magnify and prolong increases in acetylcholine receptors and resistance to nondepolarizing muscle relaxants in muscle under burned skin in rats. Anesthesiology 1994, 81: A1106